Today, I came across this article that one year ago was posted on FDA’s webpage: FDA investigates two serious adverse events associated with ImprimisRx’s compounded curcumin emulsion product for injection With this, FDA reports on an investigation related to serious adverse events following the treatment with intravenous Curcumin. Specifically, a 30-year-old female patient experienced cardiac arrest
Continue reading Avoiding Adverse Events Associated With Some Intravenous Cancer Treatments